Clinica Chimica Acta:除乳酸脱氢酶外,巴氏采血管可用于多种化学和免疫分析试剂

2019-10-18 gladiator MedSci原创

BD Barricor采血管采用了一种新型的机械分离器,旨在消除凝胶伪影,减少细胞污染,提高稳定性。在这里,我们根据BD建议,在最佳,替代和次优离心条件下,使用Beckman Coulter分析仪评估了Barricor管是否可以替代PST。

BD Barricor血管采用了一种新型的机械分离器,旨在消除凝胶伪影,减少细胞污染,提高稳定性。在这里,我们根据BD建议,在最佳,替代和次优离心条件下,使用Beckman Coulter分析仪评估了Barricor管是否可以替代PST

4家当地医院采集配对的PSTBarricor样本,并基于现场特定的预分析系统(包括自动或手动离心)进行处理。离心条件范围从1912 ×10 gmin(理想),2060g10分钟(替代)4000 ×310 gmin(最优)。此外,管体积(4.5 vs 5.5ml)也被评估。用贝克曼-库尔特DxCDxI分析仪测定了43种化学和免疫化学分析物。

研究显示,使用非最优自旋条件下的自动层前系统,除乳酸脱氢酶(LD)外,所有测试的分析物均未发现PSTBarricor之间存在偏差。进一步的调查显示显著增加LD Barricor旋转10 分钟时191220604000 ×g,从7.4 + -19.4%PST整个测量间隔(87 - 493 U / l)。较小的管容积也与较高的LD相关。尽管其他溶血标志物如钾、磷酸盐和AST没有发生变化,但LD的差异仍然存在。

研究表明,LD对巴氏管中不同的离心条件(时间和速度)最为敏感。我们建议对BD离心方案进行仔细评估,以确定在局部分析前配置下Barricor是否等同于PST

原始出处:

Joshua E. Raizman,Bobbi Lynn Goudreau,Barricor blood collection tubes are equivalent to PST for a variety of chemistry and immunoassay analytes except for lactate dehydrogenase

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849774, encodeId=8e851849e744d, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Dec 03 08:04:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928164, encodeId=ed691928164d4, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sat Nov 30 16:04:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362053, encodeId=17e1136205351, content=<a href='/topic/show?id=b3d195659ce' target=_blank style='color:#2F92EE;'>#采血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95659, encryptionId=b3d195659ce, topicName=采血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sun Oct 20 11:04:00 CST 2019, time=2019-10-20, status=1, ipAttribution=)]
    2019-12-03 windight
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849774, encodeId=8e851849e744d, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Dec 03 08:04:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928164, encodeId=ed691928164d4, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sat Nov 30 16:04:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362053, encodeId=17e1136205351, content=<a href='/topic/show?id=b3d195659ce' target=_blank style='color:#2F92EE;'>#采血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95659, encryptionId=b3d195659ce, topicName=采血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sun Oct 20 11:04:00 CST 2019, time=2019-10-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1849774, encodeId=8e851849e744d, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Tue Dec 03 08:04:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928164, encodeId=ed691928164d4, content=<a href='/topic/show?id=c56d2896643' target=_blank style='color:#2F92EE;'>#免疫分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28966, encryptionId=c56d2896643, topicName=免疫分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Sat Nov 30 16:04:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362053, encodeId=17e1136205351, content=<a href='/topic/show?id=b3d195659ce' target=_blank style='color:#2F92EE;'>#采血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95659, encryptionId=b3d195659ce, topicName=采血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sun Oct 20 11:04:00 CST 2019, time=2019-10-20, status=1, ipAttribution=)]